Now showing items 1-3 of 3

    • Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. 

      Cristofanilli, M; DeMichele, A; Giorgetti, C; Turner, NC; Slamon, DJ; Im, S-A; Masuda, N; Verma, S; Loi, S; Colleoni, M; Theall, KP; Huang, X; Liu, Y; Bartlett, CH (2018-11)
      Background The addition of palbociclib to fulvestrant improved clinical outcomes over placebo-fulvestrant in endocrine-pretreated metastatic breast cancer (MBC) patients in PALOMA-3. Here, we examined factors predictive ...
    • Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. 

      Spurdle, AB; Couch, FJ; Parsons, MT; McGuffog, L; Barrowdale, D; Bolla, MK; Wang, Q; Healey, S; Schmutzler, R; Wappenschmidt, B; Rhiem, K; Hahnen, E; Engel, C; Meindl, A; Ditsch, N; Arnold, N; Plendl, H; Niederacher, D; Sutter, C; Wang-Gohrke, S; Steinemann, D; Preisler-Adams, S; Kast, K; Varon-Mateeva, R; Ellis, S; Frost, D; Platte, R; Perkins, J; Evans, DG; Izatt, L; Eeles, R; Adlard, J; Davidson, R; Cole, T; Scuvera, G; Manoukian, S; Bonanni, B; Mariette, F; Fortuzzi, S; Viel, A; Pasini, B; Papi, L; Varesco, L; Balleine, R; Nathanson, KL; Domchek, SM; Offitt, K; Jakubowska, A; Lindor, N; Thomassen, M; Jensen, UB; Rantala, J; Borg, Å; Andrulis, IL; Miron, A; Hansen, TVO; Caldes, T; Neuhausen, SL; Toland, AE; Nevanlinna, H; Montagna, M; Garber, J; Godwin, AK; Osorio, A; Factor, RE; Terry, MB; Rebbeck, TR; Karlan, BY; Southey, M; Rashid, MU; Tung, N; Pharoah, PDP; Blows, FM; Dunning, AM; Provenzano, E; Hall, P; Czene, K; Schmidt, MK; Broeks, A; Cornelissen, S; Verhoef, S; Fasching, PA; Beckmann, MW; Ekici, AB; Slamon, DJ; Bojesen, SE; Nordestgaard, BG; Nielsen, SF; Flyger, H; Chang-Claude, J; Flesch-Janys, D; Rudolph, A; Seibold, P; Aittomäki, K; Muranen, TA; Heikkilä, P; Blomqvist, C; Figueroa, J; Chanock, SJ; Brinton, L; Lissowska, J; Olson, JE; Pankratz, VS; John, EM; Whittemore, AS; West, DW; Hamann, U; Torres, D; Ulmer, HU; Rüdiger, T; Devilee, P; Tollenaar, RAEM; Seynaeve, C; Van Asperen, CJ; Eccles, DM; Tapper, WJ; Durcan, L; Jones, L; Peto, J; dos-Santos-Silva, I; Fletcher, O; Johnson, N; Dwek, M; Swann, R; Bane, AL; Glendon, G; Mulligan, AM; Giles, GG; Milne, RL; Baglietto, L; McLean, C; Carpenter, J; Clarke, C; Scott, R; Brauch, H; Brüning, T; Ko, Y-D; Cox, A; Cross, SS; Reed, MWR; Lubinski, J; Jaworska-Bieniek, K; Durda, K; Gronwald, J; Dörk, T; Bogdanova, N; Park-Simon, T-W; Hillemanns, P; Haiman, CA; Henderson, BE; Schumacher, F; Le Marchand, L; Burwinkel, B; Marme, F; Surovy, H; Yang, R; Anton-Culver, H; Ziogas, A; Hooning, MJ; Collée, JM; Martens, JWM; Tilanus-Linthorst, MMA; Brenner, H; Dieffenbach, AK; Arndt, V; Stegmaier, C; Winqvist, R; Pylkäs, K; Jukkola-Vuorinen, A; Grip, M; Lindblom, A; Margolin, S; Joseph, V; Robson, M; Rau-Murthy, R; González-Neira, A; Arias, JI; Zamora, P; Benítez, J; Mannermaa, A; Kataja, V; Kosma, V-M; Hartikainen, JM; Peterlongo, P; Zaffaroni, D; Barile, M; Capra, F; Radice, P; Teo, SH; Easton, DF; Antoniou, AC; Chenevix-Trench, G; Goldgar, DE; ABCTB Investigators; EMBRACE Group; GENICA Network; HEBON Group; kConFab Investigators (2014-12-23)
      Introduction The distribution of histopathological features of invasive breast tumors in BRCA1 or BRCA2 germline mutation carriers differs from that of individuals with no known mutation. Histopathological features thus ...
    • Using an in-vivo syngeneic spontaneous metastasis model identifies ID2 as a promoter of breast cancer colonisation in the brain. 

      Kijewska, M; Viski, C; Turrell, F; Fitzpatrick, A; van Weverwijk, A; Gao, Q; Iravani, M; Isacke, CM (2019-01-14)
      Background Dissemination of breast cancers to the brain is associated with poor patient outcome and limited therapeutic options. In this study we sought to identify novel regulators of brain metastasis by profiling mouse ...